MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today the enrollment and dosing of the first patient in Breeze 2, the second of two pivotal Phase 3 clinical trials in Depomed’s registration program for DM-5689 (formerly referred to as Gabapentin GR®) for the treatment of menopausal hot flashes. Breeze 1, the first Phase 3 clinical trial, was initiated in September.
